<DOC>
	<DOCNO>NCT01431521</DOCNO>
	<brief_summary>This study evaluate change liver fat content follow multiple oral dos MK-4074 Pioglitazone Hydrochloride adult male female fatty liver disease . The primary hypothesis study multiple-dose administration MK-4074 200 mg twice daily 4 week result decrease hepatic fat content respect placebo adult male female participant hepatic steatosis ( i.e. , order 50 % reduction hepatic fat respect placebo expect ) .</brief_summary>
	<brief_title>Study Changes Hepatic Fat Following Administration MK-4074 Pioglitazone Hydrochloride ( MK-4074-008 )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Females must nonchildbearing potential Body mass index ( BMI ) ≥32.0 kg/m^2 In good health base medical history , physical examination , vital sign measurement , laboratory safety test No clinically significant abnormality electrocardiogram Has document hepatic fat content ≥10 % within 6 month enrollment Maintained stable weight ( history ) least 4 week Agrees initiate weight loss program agree maintain consistent dietary habit exercise routine duration study Has rating 'moderate ' 'severe ' steatosis ultrasound prestudy ( screen ) visit Change weight great 4 % prestudy visit randomization study History illness , opinion study investigator , might confound result study pose additional risk participant Liver disease fatty liver nonalcoholic steatohepatitis ( NASH ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥3x upper limit normal range Serum triglyceride level &gt; 600 mg/dL History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal , cardiovascular ( include congestive heart failure ) , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease Had abdominal surgery , gastric bypass , bowel resection , recent liver biopsy , procedure within minimum 4 week History neoplastic disease Claustrophobia contraindication magnetic resonance imaging ( MRI ) Have wash agent associate change hepatic fat use treatment Nonalcoholic fatty liver disease ( NAFLD ) NASH minimum 3 month prior Consumes excessive amount alcohol , coffee , tea , cola , caffeinated beverage Had major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week Significant multiple and/or severe allergy Intolerance hypersensitivity pioglitazone hydrochloride inactive ingredient Regular user illicit drug history drug ( include alcohol ) abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>